PE20091347A1 - Derivados de tiazol como moduladores de la actividad quinasa - Google Patents

Derivados de tiazol como moduladores de la actividad quinasa

Info

Publication number
PE20091347A1
PE20091347A1 PE2008001843A PE2008001843A PE20091347A1 PE 20091347 A1 PE20091347 A1 PE 20091347A1 PE 2008001843 A PE2008001843 A PE 2008001843A PE 2008001843 A PE2008001843 A PE 2008001843A PE 20091347 A1 PE20091347 A1 PE 20091347A1
Authority
PE
Peru
Prior art keywords
alkyl
rent
haloalkyl
rental
arylene
Prior art date
Application number
PE2008001843A
Other languages
English (en)
Inventor
M Arshad Siddiqui
Timothy J Guzi
Panduranga Adulla P Reddy
Lianyun Zhao
Tzu T Wong
Shuyi Tang
Marc A Labroli
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20091347A1 publication Critical patent/PE20091347A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDO A UN COMPUESTO DERIVADO DE TIAZOL DE FORMULA (I), DONDE LA LINEA DE GUIONES INDICA UN ENLACE OPTATIVO Y ADICIONAL, DONDE Q ES (a) O (b), Ar ES ARILENO O HETEROARILENO, DONDE EL ARILENO O HETEROARILENO ESTA UNIDO POR MEDIO DE 2 CUALESQUIERA DE SUS ATOMOS DE CARBONO ADYACENTES, Y DONDE EL GRUPO ARILENO O HETEROARILENO PUEDE ESTAR OPTATIVAMENTE SUSTITUIDO CON HASTA 4 SUSTITUYENTES SELECCIONADOS DE HALO, ALQUILO, ALCOXI, ARILOXI, ENTRE OTROS; M ES R1, -C(O)R1, -C(S)R1, ENTRE OTROS, DONDE R1 ES H, ALQUILO, ALQUENILO, ENTRE OTROS, R2 ES H, ALQUILO, HALOALQUILO, ENTRE OTROS, R3 ES H, ALQUILO, HIDROXIALQUILO, ENTRE OTROS, R3a ES H, ALQUILO, HALOALQUILO, ENTRE OTROS, R10 ES H, ALQUILO, HALOALQUILO, ENTRE OTROS, R10a ES H, ALQUILO, HALOALQUILO, ENTRE OTROS, R11 ES H, ALQUILO, HALOALQUILO, ENTRE OTROS, W ES N(R12)2-, -S-, -O-, ENTRE OTROS, DONDE R12 ES H, ALQUILO, -(ALQUILEN)m-, ENTRE OTROS, Y ES H, HALO, ALQUILO, ENTRE OTROS, Z ES -C(R8)- O -N- CUANDO EL ENLACE OPTATIVO Y ADICIONAL ESTA AUSENTE Y Z ES -C- CUANDO EL ENLACE OPTATIVO Y ADICIONAL ESTA PRESENTE, R8 ES H, ALQUILO, -OH, ENTRE OTROS, m ES 0 O 1, n ESTA EN UN RANGO DE 0 A 2, p ES 0 O 1. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE QUINASA, SIENDO UTILES PARA EL TRATAMIENTO O PREVENCION DE TRASTORNOS PROLIFERATIVOS, ARTRITIS, ALOPECIA, LESION ISQUEMICA, ENTRE OTROS
PE2008001843A 2007-10-29 2008-10-28 Derivados de tiazol como moduladores de la actividad quinasa PE20091347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98332707P 2007-10-29 2007-10-29

Publications (1)

Publication Number Publication Date
PE20091347A1 true PE20091347A1 (es) 2009-09-18

Family

ID=40251710

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001843A PE20091347A1 (es) 2007-10-29 2008-10-28 Derivados de tiazol como moduladores de la actividad quinasa

Country Status (11)

Country Link
US (1) US8476278B2 (es)
EP (1) EP2212318B1 (es)
JP (1) JP5230035B2 (es)
CN (1) CN101910165A (es)
AR (1) AR069083A1 (es)
CA (1) CA2703978A1 (es)
CL (1) CL2008003200A1 (es)
MX (1) MX2010004875A (es)
PE (1) PE20091347A1 (es)
TW (1) TW200930715A (es)
WO (1) WO2009058728A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054701A1 (en) * 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
MX2010004878A (es) * 2007-10-29 2010-05-19 Schering Corp Derivados de tioeter y eter heterociclico y metodos de uso de los mismos.
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
US8669259B2 (en) * 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN102625807B (zh) * 2009-09-08 2016-03-09 霍夫曼-拉罗奇有限公司 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
AU2011237936A1 (en) 2010-04-07 2012-10-11 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
CN102924445B (zh) * 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
NZ629499A (en) 2012-03-30 2016-05-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
BR112022023559A2 (pt) * 2020-05-21 2023-01-24 Stemsynergy Therapeutics Inc Inibidores de notch e seus usos
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495582B1 (en) 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
WO2008054701A1 (en) * 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
AU2007314342B2 (en) * 2006-10-31 2013-02-21 Merck Sharp & Dohme Corp. Anilinopiperazine Derivatives and methods of use thereof
EP2078004B1 (en) * 2006-10-31 2015-02-25 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
MX2010004876A (es) * 2007-10-29 2010-07-28 Schering Corp Derivados de diamido tiazol como inhibidores de la proteina cinasa.

Also Published As

Publication number Publication date
US20100331313A1 (en) 2010-12-30
MX2010004875A (es) 2010-05-19
EP2212318B1 (en) 2013-07-24
TW200930715A (en) 2009-07-16
CA2703978A1 (en) 2009-05-07
US8476278B2 (en) 2013-07-02
JP2011502156A (ja) 2011-01-20
CL2008003200A1 (es) 2009-11-27
EP2212318A1 (en) 2010-08-04
WO2009058728A1 (en) 2009-05-07
JP5230035B2 (ja) 2013-07-10
CN101910165A (zh) 2010-12-08
AR069083A1 (es) 2009-12-30

Similar Documents

Publication Publication Date Title
PE20091347A1 (es) Derivados de tiazol como moduladores de la actividad quinasa
AR070221A1 (es) Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
NI201000011A (es) Derivados de pirimidina 934.
PE20200608A1 (es) Nuevos derivados de azaquinolina
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
MX343596B (es) Sulfonamidas nematocidas.
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
DOP2007000079A (es) Compuestos fenil amido heterocíclicos condensados
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
AR077043A2 (es) Pirimidinonas biciclicas y sus usos
MX2011011485A (es) Sulfonamidas nematocidas.
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
TW200800945A (en) Macrocylic inhibitors of hepatitis c virus
PA8809001A1 (es) Compuestos organicos
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
JP2009511490A5 (es)
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
PE20080889A1 (es) Aminometil-4-imidazoles
DOP2012000318A (es) Compuestos heterociclicos fusionados
AR079497A1 (es) Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a

Legal Events

Date Code Title Description
FD Application declared void or lapsed